As part of the settlement
with the Justice Department, Lilly agreed to plead guilty to one
misdemeanor violation of the Food, Drug and Cosmetic Act related to the
off-label promotion of Zyprexa between 1999 and 2001. The guilty plea
says Lilly promoted the drug in elderly people as treatment for
dementia, including Alzheimer’s, although the drug isn’t approved for
such use.
…
Wealth Attraction Research
Great Health is the Truest of All Wealth!